Adial Pharmaceuticals (ADIL) Income from Discontinued Operations (2022 - 2023)
Adial Pharmaceuticals (ADIL) posted Income from Discontinued Operations of 4519243.0 for Q4 2023, up 12023.73% sequentially from 37276.0 in Q3 2023.
Adial Pharmaceuticals (ADIL) Income from Discontinued Operations (2022 - 2023) Analysis & Trends
Adial Pharmaceuticals has reported Income from Discontinued Operations for 2 years, with the latest figure at 4519243.0 in Q4 2023.
- Quarterly Income from Discontinued Operations changed N/A year-over-year to 4519243.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 2517044.0 (changed N/A YoY) and the FY2023 annual result came in at 2624798.0, changed N/A from the prior year.
- Income from Discontinued Operations advanced to 4519243.0 in Q4 2023 per ADIL's latest filing, from 37276.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at 4519243.0 in Q4 2023 and troughed at 2597674.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.52 Mn |
| Sep 30, 2023 | 37,276.00 |
| Jun 30, 2023 | -2.60 Mn |
| Sep 30, 2022 | 558,199.00 |
| Jun 30, 2022 | 610,652.00 |